Compare KXIN & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KXIN | SNOA |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | China | United States |
| Employees | 13 | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 5.8M |
| IPO Year | N/A | 2006 |
| Metric | KXIN | SNOA |
|---|---|---|
| Price | $5.30 | $1.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 60.1K | ★ 74.0K |
| Earning Date | 11-26-2019 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,529,000.00 |
| Revenue This Year | N/A | $23.00 |
| Revenue Next Year | N/A | $24.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.68 |
| 52 Week Low | $0.11 | $0.85 |
| 52 Week High | $22.00 | $6.92 |
| Indicator | KXIN | SNOA |
|---|---|---|
| Relative Strength Index (RSI) | 54.77 | 39.77 |
| Support Level | $5.30 | $1.02 |
| Resistance Level | $6.09 | $1.25 |
| Average True Range (ATR) | 0.60 | 0.06 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 64.21 | 14.95 |
Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.